Research programme: HIV vaccine - AriaVax

Drug Profile

Research programme: HIV vaccine - AriaVax

Latest Information Update: 22 Oct 2009

Price : $50

At a glance

  • Originator AriaVax
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 22 Oct 2009 Preclinical development is ongoing in US
  • 05 Feb 2007 Preclinical trials in HIV infections treatment in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top